
    
      TRANSCEND is a prospective, multi-center, single-blind, randomized, controlled,
      noninferiority clinical trial. The trial will randomize approximately 446 subjects with
      symptomatic PAD due to stenoses of the femoral and/or popliteal arteries. Subjects meeting
      eligibility criteria will be randomized 1:1 to treatment with either the SurVeil DCB or the
      IN.PACT Admiral DCB, and followed for 60 months.
    
  